XEN496 Emerging Drug Insight

“XEN496 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about XEN496 for Developmental and Epileptic Encephalopathy in the 7MM. A detailed picture of the XEN496 for Developmental and Epileptic Encephalopathy in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the XEN496 for Developmental and Epileptic Encephalopathy. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the XEN496 market forecast, analysis for Developmental and Epileptic Encephalopathy in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Developmental and Epileptic Encephalopathy.

Drug Summary

XEN496 is a pediatric formulation of ezogabine (retigabine), a neuronal KCNQ (Kv7) potassium channel modulator under development by Xenon Pharmaceuticals as a precision medicine treatment for KCNQ2-related neonatal developmental and epileptic encephalopathy (KCNQ2-DEE).

Moreover, a Phase III clinical trial, called the “EPIK” study, is underway to evaluate the efficacy, safety, and tolerability of XEN496 administered as adjunctive treatment in approximately 40 pediatric patients aged 1 month to less than 6 years with KCNQ2-DEE. Xenon anticipates that the EPIK study (NCT04639310) will be completed in the first half of 2023.

Scope of the Report

The report provides insights into:

•  A comprehensive product overview including the XEN496 description, mechanism of action, dosage and administration, research and development activities in Developmental and Epileptic Encephalopathy.
•  Elaborated details on XEN496 regulatory milestones and other development activities have been provided in this report.
•  The report also highlights the XEN496 research and development activity in Developmental and Epileptic Encephalopathy details across the United States, Europe and Japan.
•  The report also covers the patents information with expiry timeline around XEN496.
•  The report contains forecasted sales of XEN496 for Developmental and Epileptic Encephalopathy till 2032.
•  Comprehensive coverage of the late-stage emerging therapies for Developmental and Epileptic Encephalopathy.
•  The report also features the SWOT analysis with analyst views for XEN496 in Developmental and Epileptic Encephalopathy.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

XEN496 Analytical Perspective by DelveInsight

• In-depth XEN496 Market Assessment

This report provides a detailed market assessment of XEN496 in Developmental and Epileptic Encephalopathy in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• XEN496 Clinical Assessment

The report provides the clinical trials information of XEN496 for Developmental and Epileptic Encephalopathy covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

•  In the coming years, the market scenario for Developmental and Epileptic Encephalopathy is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
•  The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence XEN496 dominance.
•  Other emerging products for Developmental and Epileptic Encephalopathy are expected to give tough market competition to XEN496 and launch of late-stage emerging therapies in the near future will significantly impact the market.
•  A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of XEN496 in Developmental and Epileptic Encephalopathy.
•  Our in-depth analysis of the forecasted sales data of XEN496 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the XEN496 in Developmental and Epileptic Encephalopathy.

Key Questions

•  What is the product type, route of administration and mechanism of action of XEN496?
•  What is the clinical trial status of the study related to XEN496 in Developmental and Epileptic Encephalopathy and study completion date?
•  What are the key collaborations, mergers and acquisitions, licensing and other activities related to the XEN496 development?
•  What are the key designations that have been granted to XEN496 for Developmental and Epileptic Encephalopathy?
•  What is the forecasted market scenario of XEN496 for Developmental and Epileptic Encephalopathy?
•  What are the forecasted sales of XEN496 in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
•  What are the other emerging products available in Developmental and Epileptic Encephalopathy and how are they giving competition to XEN496 for Developmental and Epileptic Encephalopathy?
•  Which are the late-stage emerging therapies under development for the treatment of Developmental and Epileptic Encephalopathy?